Clinical Study of Autologous Hematopoietic Stem Cell Transplantation Combined With CD19-CART Treatment for Adult High-risk Acute Lymphoblastic Leukemia
Status: Recruiting
Location: See location...
Intervention Type: Biological
Study Type: Interventional
Study Phase: Phase 2
SUMMARY
To observe the efficacy and side effects of autologous hematopoietic stem cell transplantation combined with CD19-CART for adult acute lymphoblastic leukemia, and to evaluate the safety and efficacy of this regimen in the treatment of acute lymphoblastic leukemia.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 65
Healthy Volunteers: f
View:
• Adult patients with high-risk acute B-lymphoblastic leukemia
• Complete remission was achieved after induction chemotherapy, and autologous CD19-CAR-T was successfully prepared
• Eligible for autologous hematopoietic stem cell transplantation
• No major organ dysfunction
Locations
Other Locations
China
NO.288 Nanjing Road，Heping District，Tianjin, Tianjin,
RECRUITING
Tianjin
Contact Information
Primary
erlie EL Jiang
jiangerlie@ihcams.ac.cn
+86-15122538106
Time Frame
Start Date: 2024-06-25
Estimated Completion Date: 2028-05-30
Participants
Target number of participants: 20
Treatments
Experimental: Autologous hematopoietic stem cell transplantation combined with CD19-CART
Related Therapeutic Areas
Sponsors
Leads: Institute of Hematology & Blood Diseases Hospital, China
Collaborators: Juventas Cell Therapy Ltd.